> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Grant for Protalex Immune Thrombocytopenia Study
- URL: https://www.fdaweb.com/fda-grant-for-protalex-immune-thrombocytopenia-study/
- Published: 2017-08-18T12:00:00.000Z
- Updated: 2026-09-14T22:42:05.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139419

FDA’s Office of Orphan Products Development has awarded Protalex a $403,000 grant to support future clinical development activity of PRTX-100 as a treatment for immune thrombocytopenia. The grant was made under the agency’s Orphan Products Clinical Trials Grants Program, which is intended to encourage clinical development of new drugs for use in rare diseases or conditions where no current therapy exists, or where the candidate drug will be superior to an existing therapy.

PRTX-100 is a highly purified form of staphylococcal protein A, which is an immunomodulatory protein known to modify aspects of the human immune system, according to the company. Protalex is currently enrolling patients into two Phase 1/2 dose-escalating studies at several sites in the U.S. (the 202 Study) and in Europe (the 203 Study) and has so far “seen patients in each completed lower dose cohort achieve a protocol-defined platelet response,” it says.